Welcome to our dedicated page for AngioDynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices that serve interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The company's product portfolio includes market-leading systems such as the NanoKnife® system, radiofrequency ablation devices, and a variety of vascular access, angiographic, dialysis, angioplasty, and embolization products.
AngioDynamics has a strong track record of developing and bringing new technologies to market, maintaining a dynamic presence in the high-growth medical device industry. Recently, the company reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales driven by the NanoKnife platform. AngioDynamics also completed the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, significantly enhancing its financial flexibility.
In addition to financial growth, AngioDynamics continues to innovate with significant developments such as the APEX-AV study, aimed at evaluating the safety and efficacy of the AlphaVac F1885 System for treating acute pulmonary embolism. The company’s AlphaVac F1885 System has recently received FDA clearance for the treatment of pulmonary embolism, a significant milestone that expands its indication in critical medical scenarios.
With ongoing plans to transition to a fully outsourced manufacturing model and recent divestitures to streamline its portfolio, AngioDynamics is well-positioned to focus on its core strengths and drive long-term profitability. The company's net sales are projected to be between $328 to $333 million for fiscal year 2024, with an anticipated improved gross margin and reduced adjusted loss per share.
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fourth quarter and fiscal year 2022 results, highlighting a 13.2% increase in net sales, totaling $87.0 million. However, gross margin decreased to 53.4%, down 170 basis points year-over-year. The company posted a GAAP loss per share of $0.16 for the quarter. For the full year, net sales reached $316.2 million, with a 8.7% increase over the previous year, but also a GAAP loss per share of $0.68. Looking ahead, AngioDynamics anticipates fiscal year 2023 net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will release its financial results for Q4 and fiscal year 2022 on July 12, 2022, before market open. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss the results. Investors can join via phone or through a webcast available on AngioDynamics' website. A recording of the call will be accessible from 11:00 a.m. ET on July 12 until 11:59 p.m. ET on July 19. The company focuses on innovative medical technologies aimed at improving vascular health and cancer treatment.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the UBS Global Healthcare Conference on May 23, 2022, at 4:15 p.m. ET. The presentation will focus on the company's innovations in medical technology aimed at restoring blood flow, enhancing cancer treatments, and improving patient quality of life. A live webcast will be available on the company’s website, with replay options following the event. AngioDynamics is recognized for addressing critical healthcare needs with its advanced technologies.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in medical technology, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the BofA Securities Healthcare Conference on May 10, 2022, at 10:00 a.m. PT (1:00 p.m. ET). The presentation can be viewed via live webcast on the company’s website and will be available for replay afterward. AngioDynamics specializes in restoring blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative healthcare solutions.
AngioDynamics reported a net sales increase of 3.9% to $74.0 million in Q3 fiscal 2022. Med Tech sales soared 28.6%, but Med Device saw a 2.8% decline. The gross margin decreased by 190 basis points to 52.2%. The company posted a GAAP loss per share of $0.13, though adjusted EPS rose to $0.03. Key FDA approvals were achieved for AlphaVac F18, and the company initiated the PRESERVE study. Despite challenges from COVID and inflation, AngioDynamics remains optimistic about long-term growth, projecting FY2022 net sales between $310 and $315 million.
AngioDynamics, a medical technology leader, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 p.m. ET. Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will represent the company. A live webcast of the presentation will be available on AngioDynamics' website, with a replay accessible post-event. The company specializes in technologies aimed at restoring healthy blood flow and improving patient quality of life, catering to unmet medical needs.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its third-quarter fiscal year 2022 financial results on April 7, 2022, before market opening. A conference call hosted by management will commence at 8:00 a.m. ET on the same day, allowing investors to discuss the financial outcomes. Participants can join the call via phone or access the live webcast from the AngioDynamics website. The call's recording will be available for playback shortly after its conclusion. AngioDynamics specializes in innovative, minimally invasive medical devices for various healthcare applications.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that President and CEO Jim Clemmer and CFO Stephen Trowbridge will present at three investor conferences in March 2022. The conferences include:
- Oppenheimer Virtual Healthcare Conference: March 15, 2022, at 8:40 a.m. ET
- Barclays Global Healthcare Conference: March 16, 2022, in Miami Beach, FL, at 9:00 a.m. ET
- KeyBanc Virtual Life Sciences & MedTech Investor Forum: March 22, 2022, at 3:45 p.m. ET
Live webcasts will be available on the company's website.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:00 a.m. ET. This event is designed for BTIG clients. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse product line including ablation systems and vascular access products. For more details, visit www.angiodynamics.com.
AngioDynamics reported fiscal Q2 2022 net sales of $78.3 million, up 7.6% year-over-year. Med Tech sales surged 36.4%, while Med Device grew 0.8%. Gross margin declined to 51.8%, impacted by a $4 million backlog due to ongoing supply chain challenges. The company recorded a GAAP loss per share of $0.21 and an adjusted loss of $0.02. Full market release of the AlphaVac device occurred post-quarter. Fiscal year 2022 revenue guidance remains at $310-315 million, but gross margin guidance was revised down to 52.0%-54.0%.
FAQ
What is the current stock price of AngioDynamics (ANGO)?
What is the market cap of AngioDynamics (ANGO)?
What does AngioDynamics, Inc. specialize in?
What are some recent achievements of AngioDynamics, Inc.?
What is the AlphaVac F1885 System?
What financial performance did AngioDynamics report for the first quarter of fiscal year 2024?
What are AngioDynamics' future plans for manufacturing?
Where does AngioDynamics generate the majority of its revenue?
What is the NanoKnife® system?
How does AngioDynamics plan to enhance its focus on core strengths?
What is the APEX-AV study?
How does AngioDynamics contribute to the medical device industry?
